Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia.

Girmenia C, Micozzi A, Piciocchi A, Gentile G, Di Caprio L, Nasso D, Minotti C, Capria S, Cartoni C, Alimena G, Meloni G, Amadori S, Foà R, Venditti A.

Leuk Res. 2014 Apr;38(4):469-74. doi: 10.1016/j.leukres.2014.01.007. Epub 2014 Jan 20.

PMID:
24534569
2.
3.

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.

Girmenia C, Frustaci AM, Gentile G, Minotti C, Cartoni C, Capria S, Trisolini SM, Matturro A, Loglisci G, Latagliata R, Breccia M, Meloni G, Alimena G, Foà R, Micozzi A.

Haematologica. 2012 Apr;97(4):560-7. doi: 10.3324/haematol.2011.053058. Epub 2011 Nov 18.

4.
5.

Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.

Schrenk KG, Schnetzke U, Stegemann K, von Lilienfeld-Toal M, Hochhaus A, Scholl S.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1661-8. doi: 10.1007/s00432-015-1962-x. Epub 2015 Mar 24.

PMID:
25800622
6.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90. Epub 2003 Aug 19.

PMID:
12928754
7.

Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

Tavernier E, Le QH, Elhamri M, Thomas X.

Leuk Res. 2003 Mar;27(3):205-14.

PMID:
12537972
8.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey E.

Blood. 2009 Jan 1;113(1):28-36. doi: 10.1182/blood-2008-05-157065. Epub 2008 Sep 30.

9.

Long-term outcomes of de novo acute myeloid leukemia in Thai patients.

Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.

J Med Assoc Thai. 2009 Sep;92(9):1143-9.

PMID:
19772172
10.

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.

Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M, Martinelli G, Piccaluga PP, Paolini S, De Rosa F, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, Roccaro AM, Filì C, Fanin R, Baccarani M, Russo D.

Eur J Haematol. 2008 Nov;81(5):354-63. doi: 10.1111/j.1600-0609.2008.01122.x. Epub 2008 Aug 19.

PMID:
18637030
11.

Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.

Ornstein MC, Mukherjee S, Mohan S, Elson P, Tiu RV, Saunthararajah Y, Kendeigh C, Advani A, Kalaycio M, Maciejewski JP, Sekeres MA.

Am J Hematol. 2014 Feb;89(2):168-73. doi: 10.1002/ajh.23605. Epub 2013 Nov 21.

12.
13.

Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.

Rizzieri DA, O'Brien JA, Broadwater G, Decastro CM, Dev P, Diehl L, Beaven A, Lagoo A, Gockerman JP, Chao NJ, Moore JO.

Cancer. 2009 Jul 1;115(13):2922-9. doi: 10.1002/cncr.24379.

14.

[Long-term survival results according to cytogenetic risk in patients with acute myeloid leukemia--singl center experience].

Piatkowska-Jakubas B, Mensah-Glanowska P, Salamańczuk Z, Skotnicki AB.

Przegl Lek. 2011;68(6):291-5. Polish.

PMID:
22039664
15.

Posaconazole prophylaxis in patients with acute myelogenous leukaemia--results from an observational study.

Egerer G, Geist MJ.

Mycoses. 2011 Jan;54 Suppl 1:7-11. doi: 10.1111/j.1439-0507.2010.01979.x.

PMID:
21126266
16.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terré C, Fenaux P, Bordessoule D, Celli-Lebras K, Castaigne S, Dombret H.

J Clin Oncol. 2013 Jan 20;31(3):321-7. doi: 10.1200/JCO.2011.40.3642. Epub 2012 Dec 17.

PMID:
23248249
17.

Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients.

Michallet M, Bénet T, Sobh M, Kraghel S, El Hamri M, Cannas G, Nicolini FE, Labussière H, Ducastelle S, Barraco F, Thomas X, Chelghoum Y, Nicolle MC, Bienvenu AL, Persat F, De Monbrison F, Picot S, Vanhems P.

Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):991-7. doi: 10.1007/s10096-011-1397-5. Epub 2011 Sep 10.

PMID:
21909650
18.

Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil.

Nucci M, Garnica M, Gloria AB, Lehugeur DS, Dias VC, Palma LC, Cappellano P, Fertrin KY, Carlesse F, Simões B, Bergamasco MD, Cunha CA, Seber A, Ribeiro MP, Queiroz-Telles F, Lee ML, Chauffaille ML, Silla L, de Souza CA, Colombo AL.

Clin Microbiol Infect. 2013 Aug;19(8):745-51. doi: 10.1111/1469-0691.12002. Epub 2012 Sep 25.

19.

Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors.

Wiley JM, Smith N, Leventhal BG, Graham ML, Strauss LC, Hurwitz CA, Modlin J, Mellits D, Baumgardner R, Corden BJ, et al.

J Clin Oncol. 1990 Feb;8(2):280-6.

PMID:
2299371
20.

Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.

Colovic N, Tomin D, Vidovic A, Suvajdzic N, Jankovic G, Palibrk V, Djunic I, Djurasinovic V, Virijevic M.

Biomed Pharmacother. 2012 Dec;66(8):578-82. doi: 10.1016/j.biopha.2011.11.006. Epub 2011 Dec 21.

PMID:
23085253

Supplemental Content

Support Center